<?xml version="1.0" encoding="UTF-8"?>
<fig id="fig18" position="float">
 <label>Figure 18</label>
 <caption>
  <p>Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpG
   <sup>m</sup> adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce cell-to-cell virus spread 
   <italic>in vitro</italic>. Bottom right: CaP nanovaccines were able to immunize mice against HSV-1. Reproduced with permission from ref (
   <xref ref-type="bibr" rid="ref153">153</xref>). Copyright 2019 Elsevier B.V.
  </p>
 </caption>
 <graphic xlink:href="nn0c04117_0018" id="gr18" position="float" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
